alendronate has been researched along with Ulcer in 16 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate is commonly used in the treatment of osteoporosis and other bone diseases." | 8.88 | Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature. ( Bee, J; Hanna, J; Sataloff, RT, 2012) |
| "We describe three patients who had severe esophagitis shortly after starting to take alendronate and also analyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveillance." | 8.79 | Esophagitis associated with the use of alendronate. ( Daifotis, A; de Groen, PC; Freedholm, D; Hirsch, LJ; Lubbe, DF; Pinkas, H; Pryor-Tillotson, S; Seleznick, MJ; Stephenson, W; Wang, KK, 1996) |
| "We present a case of esophageal ulcerations caused by alendronate (Fosamax), a recently marketed medication." | 8.79 | A new probable increasing cause of esophageal ulceration: alendronate. ( Colina, RE; Kikendall, JW; Smith, M; Wong, RK, 1997) |
| " We used health registers to identify predictors of new major osteoporotic fractures in patients adhering to alendronate." | 7.79 | Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. ( Abrahamsen, B; Eastell, R; Eiken, PA; Rubin, KH, 2013) |
| "Alendronate is commonly used in the treatment of osteoporosis and other bone diseases." | 4.88 | Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature. ( Bee, J; Hanna, J; Sataloff, RT, 2012) |
| "We describe three patients who had severe esophagitis shortly after starting to take alendronate and also analyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveillance." | 4.79 | Esophagitis associated with the use of alendronate. ( Daifotis, A; de Groen, PC; Freedholm, D; Hirsch, LJ; Lubbe, DF; Pinkas, H; Pryor-Tillotson, S; Seleznick, MJ; Stephenson, W; Wang, KK, 1996) |
| "We present a case of esophageal ulcerations caused by alendronate (Fosamax), a recently marketed medication." | 4.79 | A new probable increasing cause of esophageal ulceration: alendronate. ( Colina, RE; Kikendall, JW; Smith, M; Wong, RK, 1997) |
| " We used health registers to identify predictors of new major osteoporotic fractures in patients adhering to alendronate." | 3.79 | Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. ( Abrahamsen, B; Eastell, R; Eiken, PA; Rubin, KH, 2013) |
| "Ingestion of alendronate sodium (Fosamax) by osteoporotic patients can be associated with esophagitis and esophageal ulcer." | 3.70 | Alendronate-associated esophageal injury: pathologic and endoscopic features. ( Abraham, SC; Cruz-Correa, M; Lee, LA; Wu, TT; Yardley, JH, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (68.75) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakaida, H | 1 |
| Yuasa, H | 1 |
| Fukutome, K | 1 |
| Takeuchi, K | 1 |
| Ueda, K | 1 |
| Muto, M | 1 |
| Chiba, T | 1 |
| Abrahamsen, B | 1 |
| Rubin, KH | 1 |
| Eiken, PA | 1 |
| Eastell, R | 1 |
| Hanna, J | 1 |
| Bee, J | 1 |
| Sataloff, RT | 1 |
| Terashima, T | 1 |
| Hiramatsu, K | 1 |
| Shimatani, A | 1 |
| Matsuda, M | 1 |
| Ogino, H | 1 |
| Satomura, Y | 1 |
| Noda, Y | 1 |
| Maconi, G | 1 |
| Bianchi Porro, G | 1 |
| Abdelmalek, MF | 1 |
| Douglas, DD | 1 |
| de Groen, PC | 1 |
| Lubbe, DF | 1 |
| Hirsch, LJ | 2 |
| Daifotis, A | 1 |
| Stephenson, W | 1 |
| Freedholm, D | 1 |
| Pryor-Tillotson, S | 1 |
| Seleznick, MJ | 1 |
| Pinkas, H | 1 |
| Wang, KK | 1 |
| Castell, DO | 1 |
| Liberman, UI | 1 |
| Sorrentino, D | 1 |
| Trevisi, A | 1 |
| Bernardis, V | 1 |
| DeBiase, F | 1 |
| Labombarda, A | 1 |
| Bartoli, E | 1 |
| Colina, RE | 1 |
| Smith, M | 1 |
| Kikendall, JW | 1 |
| Wong, RK | 1 |
| Tursi, A | 1 |
| Cuoco, L | 1 |
| Cammarota, G | 1 |
| Papa, A | 1 |
| De Vitis, I | 1 |
| Fedeli, G | 1 |
| Gasbarrini, G | 1 |
| Kaye, PS | 1 |
| Abraham, SC | 1 |
| Cruz-Correa, M | 1 |
| Lee, LA | 1 |
| Yardley, JH | 1 |
| Wu, TT | 1 |
3 reviews available for alendronate and Ulcer
| Article | Year |
|---|---|
Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Overdose; Hemoptysis; Humans; Laryngeal Di | 2012 |
Esophagitis associated with the use of alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Esophagitis; Female; Humans; Osteoporosis, Pos | 1996 |
A new probable increasing cause of esophageal ulceration: alendronate.
Topics: Adult; Alendronate; Biopsy; Esophageal Diseases; Esophagogastric Junction; Esophagoscopy; Female; Hu | 1997 |
1 trial available for alendronate and Ulcer
| Article | Year |
|---|---|
Esophagitis and alendronate.
Topics: Alendronate; Diphosphonates; Esophageal Diseases; Esophagitis; Female; Humans; Osteoporosis, Postmen | 1996 |
12 other studies available for alendronate and Ulcer
| Article | Year |
|---|---|
Pharyngolaryngeal ulcers associated with the improper use of alendronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Humans; Laryngeal Diseases; Osteoporosi | 2017 |
A case of esophageal ulcer caused by alendronate sodium tablets.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Endoscopy, Gastrointes | 2011 |
Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Comorbid | 2013 |
An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Esophageal Diseases; Esophag | 2006 |
Multiple ulcerative esophagitis caused by alendronate.
Topics: Alendronate; Diphosphonates; Esophagitis; Female; Humans; Middle Aged; Ulcer | 1995 |
Alendronate-induced ulcerative esophagitis.
Topics: Aged; Alendronate; Diphosphonates; Drug Interactions; Esophagitis; Humans; Male; Ulcer | 1996 |
Postmarketing surveillance indicates need for better education of patients taking alendronate.
Topics: Alendronate; Diphosphonates; Esophageal Diseases; Esophagitis; Humans; Patient Education as Topic; P | 1996 |
"Pill esophagitis"--the case of alendronate.
Topics: Alendronate; Diphosphonates; Esophagitis; Female; Humans; Osteoporosis, Postmenopausal; Ulcer | 1996 |
Esophageal ulceration due to alendronate.
Topics: Adult; Alendronate; Esophageal Diseases; Humans; Male; Osteoporosis; Ulcer | 1996 |
Ulcerative oesophagitis due to alendronate.
Topics: Aged; Alendronate; Esophagitis; Female; Humans; Ulcer | 1997 |
Gastric hemorrhage and ulceration in hiatal hernia sac associated with alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Esophageal Diseases; Female; Gastrointestinal Hemorrhage; Hern | 1999 |
Alendronate-associated esophageal injury: pathologic and endoscopic features.
Topics: Aged; Aged, 80 and over; Alendronate; Esophageal Diseases; Esophagitis; Esophagoscopy; Esophagus; Fe | 1999 |